Recent advances in pulmonary arterial hypertension
Standard
Recent advances in pulmonary arterial hypertension. / Wilkins, Martin R; Aman, Jurjan; Harbaum, Lars; Ulrich, Anna; Wharton, John; Rhodes, Christopher J.
in: F1000 Research, Jahrgang 7, 2018.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recent advances in pulmonary arterial hypertension
AU - Wilkins, Martin R
AU - Aman, Jurjan
AU - Harbaum, Lars
AU - Ulrich, Anna
AU - Wharton, John
AU - Rhodes, Christopher J
PY - 2018
Y1 - 2018
N2 - Pulmonary arterial hypertension (PAH) is a rare disorder with a high mortality rate. Treatment options have improved in the last 20 years, but patients still die prematurely of right heart failure. Though rare, it is heterogeneous at the genetic and molecular level, and understanding and exploiting this is key to the development of more effective treatments. BMPR2, encoding bone morphogenetic receptor type 2, is the most commonly affected gene in both familial and non-familial PAH, but rare mutations have been identified in other genes. Transcriptomic, proteomic, and metabolomic studies looking for endophenotypes are under way. There is no shortage of candidate new drug targets for PAH, but the selection and prioritisation of these are challenges for the research community.
AB - Pulmonary arterial hypertension (PAH) is a rare disorder with a high mortality rate. Treatment options have improved in the last 20 years, but patients still die prematurely of right heart failure. Though rare, it is heterogeneous at the genetic and molecular level, and understanding and exploiting this is key to the development of more effective treatments. BMPR2, encoding bone morphogenetic receptor type 2, is the most commonly affected gene in both familial and non-familial PAH, but rare mutations have been identified in other genes. Transcriptomic, proteomic, and metabolomic studies looking for endophenotypes are under way. There is no shortage of candidate new drug targets for PAH, but the selection and prioritisation of these are challenges for the research community.
KW - Journal Article
KW - Review
U2 - 10.12688/f1000research.14984.1
DO - 10.12688/f1000research.14984.1
M3 - SCORING: Review article
C2 - 30079232
VL - 7
ER -